The data integration challenge: Is your “more-data” strategy holding you back?

For decades, the standard response to a difficult decision in drug discovery was simple

Get more data. Sequence more. Screen more. License another study.

But that instinct has quietly stopped paying off.

In today’s data-rich R&D environment, the binding constraint isn’t a lack of information—it’s the fragmented domain data you already own but cannot see. When your genomics results, clinical records, and literature exist in disconnected silos, your team isn’t just wasting hours on manual preparation; you are incurring massive missed-opportunity costs.

What you’ll learn

The next breakthrough in early-stage drug discovery productivity will not come from collecting more data. It will come from connecting the data that already exists.

• Why the “More-Data Reflex” is broken: Understand why volume is no longer the metric of success and how to stop the cycle of infinite data accumulation.
• How to bridge the “Domain Data Gap”: Gain actionable strategies for linking biological entities—like genes and chemicals—directly to clinical outcomes to create a unified strategic asset.
• The path to defensible, trustworthy AI: Learn how to move from “fast answers” to conclusions that are backed by traceable evidence and provenance.
• How to turn architecture into advantage: See why the organizations that win are those that prioritize integrated R&D strategies, allowing them to turn research into decisions faster than the competition.

Retire a strategy that no longer works and start building a foundation that scales.